The published manuscript detailed the safety and efficacy results of INT230-6, Intensity’s intratumoral therapy for treating metastatic or refractory cancers. The data showed a 75% disease control ...
TipRanks on MSN
Transcenta’s Partner Inhibrx Reports Positive Phase 2 Results for Ozekibart in Chondrosarcoma
An announcement from Transcenta Holding Limited ( ($HK:6628) ) is now available. Transcenta Holding Limited announced that its partner, Inhibrx ...
Intensity Therapeutics shares plunged 31.9% after-hours following the publication of Phase 1/2 trial results for its cancer ...
Trials-in-progress poster of ongoing pivotal Phase 3 trial of DNA-mediated immunotherapy accepted at both IGCS and ESMO Congress 2025 ...
Apogee Therapeutics, Inc. targets atopic dermatitis with APG777, aiming to outperform Dupixent. Learn more about APGE stock ...
Autolus Therapeutics plc (NASDAQ: AUTL) is one of the best stocks under $5 with highest upside potential. Autolus ...
Intellia Therapeutics, Inc. is rated Hold due to uncertainty from dosing pause in its MAGNITUDE program for ATTR. Learn more ...
The U.S. Food and Drug Administration (FDA) has granted fast track designation to the antibody-drug conjugate JSKN003 for the ...
Intensity Therapeutics, Inc. (Nasdaq: INTS) ("Intensity" or "the Company"), a late-stage clinical biotechnology company ...
Zink opened the session by recapping key efficacy data for ruxolitinib cream in non-segmental vitiligo from the TRuE-V1/2 ...
CDX-622 potently neutralizes TSLP and soluble SCF and leads to mast cell reduction in preclinical models. CDX-622 preferentially inhibits the soluble form of SCF over the membrane form, which may lead ...
Leading low carbon liquid fuels (LCLF) company HAMR Energy and Supercritical Solutions (Supercritical) today announced the completion of the first phases of a feasibility study into next-generation, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback